KinDex was established to focus on the discovery and development of molecules that modulate key regulatory networks associated with chronic disease
KinDex’s molecules have demonstrated efficacy in in vitro and in vivo models of peripheral insulin resistance and inflammation. We have successfully completed Phase 1 safety studies of our most advanced drug candidate, KDT501, and have initiated a proof-of-concept clinical trial in metabolically disturbed patients . Our next goal is to study the effects of KDT501 in patients with Polycystic Ovary Syndrome (PCOS).
PCOS is a common endocrine disorder affecting between 5 and 10 % of women of reproductive age1. Many PCOS patients have a family history of diabetes or insulin resistance or a close relative who is similarly affected by androgen excess. Irregular ovulation in combination with excess androgens, excess hair growth (hirsutism), acne and obesity can all occur in women with PCOS. Women with PCOS are at greater risk for type 2 diabetes and cardiovascular disease and possibly hypertension and abnormal lipid levels.
The annual cost in 2005 in the USA for diagnosis and treatment of PCOS was $4.36 billion2.
